Piper Sandler Upgrades Halozyme Therapeutics to Overweight, Raises Price Target to $27

Piper Sandler analyst Joseph Catanzaro upgrades Halozyme Therapeutics (NASDAQ:HALO) from Neutral to Overweight and raises the price target from $18 to $27.

Benzinga · 02/05/2020 10:27

Piper Sandler analyst Joseph Catanzaro upgrades Halozyme Therapeutics (NASDAQ:HALO) from Neutral to Overweight and raises the price target from $18 to $27.